Maternal Use of Immunostimulating or Immunosuppressive Drugs and Infant Congenital Malformations
Available information on the use of immunostimulating and immunosuppressive drugs during pregnancy is limited. It is generally argued that with the exception of mycophenylate mofetil no certain teratogenic effect is seen of these drugs. The data presented here indicate that use of azathioprine or its active metabolite 6-mercaptopurine is associated with an increased risk of cardiac septum defects and perhaps of hypospadias. Similarly, tacrolimus is generally regarded as without risk for congenital malformations but in a rather small material an increased risk seemed to exist but it was based on few exposed cases and needs confirmation.
- Bazzani C, Scrivo R, Andreoli L, Baldissera E, Biggioggero M, Canti V, Gerosa M, Pontikaki I, Ramon V, Trespidi L, Zatti S, Caporali T, Gloria R, Iannone F, Lojacono A, Meroni P, Montecucco C, Motta M, Sabbadini MG, Valesini G, Tincani A. Prospectively followed pregnancies in patients with inflammatory arthritis taking biological drugs: an Italian multicenter study. Clin Exp Rheumatol. 2015;33:688–93.PubMedGoogle Scholar
- Clowse MEB, Scheuerie AE, Chambers C, Afzan A, Kimball AB, Cush JJ, Cooney M, Shaughnessy L, Vanderkelen M, Förger F. Pregnancy outcomes after exposure to certolizumab pegol: updated results from a pharmacovigilance safety database. Arthritis Rheumatol. 2018;70(9):1399–407. https://doi.org/10.1002/art.40508.CrossRefPubMedPubMedCentralGoogle Scholar
- Coyle PK, Sinclair SM, Scheuerle AE, Thorpt JM, Albano JD, Rametta MJ. Final results of the Betaseron (interferon β-1b) pregnancy registry: s prospective observational study of birth defects and pregnancy-related adverse events. BMJ Open. 2014;4:e004536. https://doi.org/10.1136/bmjopen-2013-004538.CrossRefPubMedPubMedCentralGoogle Scholar
- Hoeltzenbein M, Elefant E, Vial T, Finkel-Pekarsky V, Stephens S, Clementi M, Allignol A, Weber-Schoendorfer C, Schaefer C. Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. Am J Med Genet A. 2012;158A:588–96.CrossRefGoogle Scholar
- Seirafi M, de Vroey B, Amiot A, Seksik P, Roblin X, Allez M, Peyrin-Biroulet L, Marteau P, Cadiot G, Laharie D, Boureille A, De Vos M, Savoye G, Rahier J-F, Carbonnel F, Bonaz B. Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease. Aliment Pharmacol Ther. 2014;40:363–73.CrossRefGoogle Scholar
- Thiel S, Langer-Gould A, Rockhoff M, Haghikia A, Queisser-Wahrendorf A, Gold R, Hellwig K. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis—a prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry. Mult Scler. 2016;22:801–9.CrossRefGoogle Scholar